Is TEM a good stock to buy? We came across a bullish thesis on Tempus AI, Inc. on Joe Gannon’s Substack by Gannon Capital. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.’s share was trading at $56.78 as of April 20th. TEM’s trailing P/E was 39.30 according to Yahoo Finance.
Tempus AI, Inc. operates as a healthcare technology company in the United States. TEM founded in 2015 by Eric Lefkofsky, was born out of frustration with the fragmented nature of cancer care, where clinical and molecular data existed in silos without integration. The company set out to build a unified “operating system” for human biology by linking genomic data with real-world patient outcomes.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Through an aggressive early strategy of partnering with hospitals and subsidizing sequencing, Tempus effectively acquired vast amounts of structured data, laying the foundation for a powerful data flywheel. Over time, it expanded beyond oncology into broader disease areas and scaled its platform, culminating in its 2024 IPO and subsequent acquisitions such as Ambry Genetics and Paige.AI, which enabled a fully integrated, closed-loop dataset spanning genetic, clinical, and imaging information.
At its core, Tempus operates a two-sided model where its genomics business generates revenue while simultaneously feeding its high-margin data platform. Each diagnostic test not only delivers actionable insights to physicians but also enriches Tempus’s proprietary dataset, which is then monetized through applications like its Lens platform and AI-driven trial matching for pharmaceutical companies. This creates a unique model where the same data asset is monetized twice, driving both growth and margin expansion. With over 200 petabytes of data and connections to a significant portion of U.S. oncologists, the company has built a self-reinforcing network effect that is difficult to replicate.
The investment thesis centers on Tempus as an AI infrastructure play rather than a traditional diagnostics company, aiming to become the default platform for clinical decision-making and drug development. While risks remain around regulation, data privacy, and profitability, the company’s recent shift to positive adjusted EBITDA and continued strong growth in its high-margin data segment suggest it is approaching a critical inflection point, with substantial long-term upside if execution continues.
Previously, we covered a bullish thesis on Tempus AI, Inc. (TEM) by Oliver | MMMT Wealth in April 2025, which highlighted the company’s undervaluation at 6.0x NTM sales, strong 35% revenue growth outlook, and diversified exposure across genomics, data licensing, and AI applications. TEM’s stock price has appreciated by approximately 31.34% since our coverage. Joe Gannon shares a similar view but emphasizes on its data flywheel and AI infrastructure positioning.
Tempus AI, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held TEM at the end of the fourth quarter which was 32 in the previous quarter. While we acknowledge the risk and potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEM and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
